Showing results (101-110 of 254) with videos related to

Sort By:
Pageof 26
AIDS Research and Human Retroviruses|February 17, 2016
Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to Antiretroviral Drugs During Pregnancy in Latin America and the CaribbeanAlicen B Spaulding, Qilu Yu, Lucy Civitello, et al.
The Journal of Clinical Endocrinology and Metabolism|August 31, 2012
Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infectionPeter L Havens, Kathleen Mulligan, Rohan Hazra, et al.
AIDS (London, England)|June 12, 2010
Correlates of spontaneous viral control among long-term survivors of perinatal HIV-1 infection expressing human leukocyte antigen-B57Yanhua Tang, Sihong Huang, Jacqueline Dunkley-Thompson, et al.
Journal of the Pediatric Infectious Diseases Society|May 21, 2016
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young AdultsKajal B Larson, Tim R Cressey, Ram Yogev, et al.
Journal of the Pediatric Infectious Diseases Society|April 23, 2016
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young AdultsTim R Cressey, Ram Yogev, Andrew Wiznia, et al.
AIDS Research and Human Retroviruses|May 29, 2014
Short communication: kidney dysfunction among HIV-infected children in Latin America and the CaribbeanCristina B Hofer, D Robert Harris, Ricardo Hugo de Oliveira, et al.
Plos One|July 5, 2013
Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian PatientsSasisopin Kiertiburanakul, Romanee Chaiwarith, Sunee Sirivichayakul, et al.
AIDS (London, England)|March 28, 2014
Biomarkers and neurodevelopment in perinatally HIV-infected or exposed youth: a structural equation model analysisSuad Kapetanovic, Ray Griner, Bret Zeldow, et al.
AIDS (London, England)|February 8, 2011
Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapyEllen G Chadwick, Ram Yogev, Carmelita G Alvero, et al.
Pageof 26